Prognostic markers of primary progressive multiple sclerosis evolution are needed. We investigated the added value of magnetic resonance imaging measures of brain and cervical cord damage in predicting long-term clinical worsening of primary progressive multiple sclerosis compared to simple clinical assessment. In 54 patients, conventional and diffusion tensor brain scans and cervical cord T 1 -weighted scans were acquired at baseline and after 15 months. Clinical evaluation was performed after 5 and 15 years in 49 patients. Lesion load, brain and cord atrophy, mean diffusivity and fractional anisotropy values from the brain normalappearing white matter and grey matter were obtained. Using linear regression models, we screened the clinical and imaging variables as independent predictors of 15-year disability change (measured on the expanded disability status scale). At 15 years, 90% of the patients had disability progression. Integrating clinical and imaging variables at 15 months predicted disability changes at 15 years better than clinical factors at 5 years (R 2 = 61% versus R 2 = 57%). The model predicted long-term disability change with a precision within one point in 38 of 49 patients (77.6%). Integration of clinical and imaging measures allows identification of primary progressive multiple sclerosis patients at risk of long-term disease progression 4 years earlier than when using clinical assessment alone.
Introduction
Now that treatments for primary progressive multiple sclerosis (PPMS) are starting to appear in clinical use (Tourbah et al., 2016; Montalban et al., 2017) , there is an increasing need to identify those PPMS patients who will have a more severe clinical outcome in the long term, in order to inform treatment decisions and optimize patient management.
An observational cohort study of 54 PPMS patients is ongoing at our Unit, with clinical and brain and spinal cord MRI evaluations at baseline and after 15 months . A clinical re-evaluation was done after 5 years (Rovaris et al., 2006) . A lower level of disability and a more severe baseline grey matter damage identified PPMS patients with an increased risk of disease progression at 5 years.
Here, we report the results of the 15-year clinical followup of these patients. We investigated the added value of conventional and advanced MRI measures of brain and cervical cord damage in predicting the long-term clinical worsening of PPMS, in comparison to simple clinical assessment.
Materials and methods

Ethics committee approval
Approval was received from the local ethical standards committee on human experimentation, and written informed consent was obtained from all subjects before study initiation and at the 15-year evaluation.
Patients
We enrolled 54 PPMS patients (female/male: 27/27; mean age at study entry = 51.3 years, range = 25-68 years; median disease duration at study entry = 10.0 years, range = 2-26 years) in this long-term, observational study (Rovaris et al., 2006) . We asked all patients who had taken part in a short-term follow-up study to participate in the present study . Neurological assessment and Expanded Disability Status Scale (EDSS) rating were performed at the time of the MRI, and after a median period of 15.0 months (n = 54) and 56 months (n = 52) (Rovaris et al., 2006) from study entry. In the present study, the median length of the neurological follow-up was 15.1 years [interquartile range (IQR) = 13.9-15.4 years]. Any EDSS change was always confirmed by a second visit after a further 3 months. A comprehensive description of the study design, inclusion/exclusion criteria and clinical characteristics of the subjects at study entry is provided elsewhere .
Image acquisition and analysis
Using a 1.5 T scanner, the following brain MRI scans were obtained at study entry and at 15 months: (i) axial dualecho turbo spin-echo; (ii) axial T 1 -weighted conventional spin-echo; and (iii) axial echo-planar pulsed-gradient spinecho, with diffusion gradients applied in eight non-collinear directions. In the same scanning session, a cervical cord 3D T 1 -weighted magnetization prepared rapid acquisition gradient echo (MP-RAGE) sequence was also acquired. The complete image acquisition scheme is detailed elsewhere .
All image acquisition and analysis was performed at the Neuroimaging Research Unit, San Raffaele Hospital, Milan, as previously described (Rovaris et al., 2006) .
Brain T 2 -hyperintense and T 1 -hypointense lesion volumes were measured using a semi-automated local thresholding technique. At 15 months, the numbers of new T 2 -hyperintense and new T 1 -hypointense brain lesions were counted. Baseline normalized brain volume and 15-month percentage brain volume changes were estimated using Structural Imaging Evaluation of Normalized Atrophy software and its longitudinal version (Smith et al., 2002) .
Mean diffusivity and fractional anisotropy maps were produced from the diffusion-weighted images, and co-registered with the dual echo images as detailed elsewhere (Rovaris et al., 2006) .
Average lesion mean diffusivity and fractional anisotropy were computed as previously described . Following automated segmentation of brain grey matter, white matter and CSF from proton density-and T 2 -weighted images , the resulting masks for each tissue were superimposed onto the mean diffusivity and fractional anisotropy maps, where T 2 -hyperintense lesions were previously masked out, and the corresponding mean diffusivity histograms of the normal-appearing white matter and grey matter as well as fractional anisotropy histograms of the normal-appearing white matter were produced. For all histograms, the average mean diffusivity and fractional anisotropy values were calculated.
Cord cross-sectional area was measured on the 3D T 1 -weighted scans.
Statistical analysis
The mean and standard deviation of the MRI-derived metrics were compared between baseline and 15 months. The EDSS change at 15 years was assessed using both parametric and non-parametric analyses. Since the results did not differ, the parametric analysis is presented. Pearson correlation coefficient was used in the univariate statistical analysis (adjusted for follow-up duration) to assess the relationship between delta EDSS at 15 years and the clinical/MRI factors.
Linear regression models were used to screen the clinical and MRI variables as independent predictors of change in EDSS between baseline and 15 years, using a stepwise variable selection procedure. The stepwise procedure is a combination of forward and backward selection. In each step, each variable is considered for addition to or subtraction from the set of covariates based on an F-test with a P-value for inclusion of 0.1. Five models were implemented: the first three models assessed 15-year EDSS changes using clinical factors only (at baseline, 15 months and 5 years); the last two models assessed 15-year EDSS changes using clinical and MRI factors (at baseline and at 15 months). The models were compared using R 2 . The discriminating ability of the five models was tested using the leave-one-out cross-validation method. With this method and for each observation, the final model is refitted after leaving that observation out of the dataset, and the predicted value for that observation is then computed. This procedure is run n times (n = sample size) and the discriminating ability of the final model is estimated as the proportion of patients whose clinical evolution is correctly predicted.
Results
Five patients of the original cohort (Rovaris et al., 2006) did not undertake the 15-year visit (unwilling to attend or unreachable). Two patients had died between Years 5 and 15, for reasons due to multiple sclerosis (pneumonia), and were given an EDSS of 10.
The median EDSS scores were 6.0 (IQR = 4.5-6.5) at baseline and 7.5 (IQR = 7.0-8.0) at 15 years (P 5 0.001). During the follow-up, 44 (89.8%) patients experienced an increase in their EDSS, whereas the remaining five (10.2%) stayed clinically stable. At baseline, 36 patients were not receiving any disease-modifying treatment, nine received azathioprine, four mitoxantrone and five methotrexate. At 15 years, two patients had stopped azathioprine, two mitoxantrone and four methotrexate, i.e. 44 patients were not receiving any disease-modifying treatment. Table 1 reports MRI data at baseline and 15 months from patients undergoing the long-term follow-up. Significant increases in T 2 and T 1 lesion volumes and decreases in cord cross-sectional area were detected. Table 2 reports the results of the univariate analysis of correlations between clinical/MRI variables and delta-EDSS at 15 years. Delta-EDSS at 15 years did not differ between males (mean change + 2.0) and females (mean change + 1.9) (P = 0.81). Table 3 summarizes the results of the five linear regression models implemented. Clinical models showed that baseline EDSS and its change during the follow-up predicted long-term EDSS change (R 2 from 0.42 to 0.57). Integrating clinical and MRI variables at 15 months predicted EDSS changes at 15 years better than clinical factors alone at 5 years (R 2 = 61% versus R 2 = 57%). The use of such a model, which included baseline EDSS and grey matter mean diffusivity, as well as the number of new T 1 hypointense lesions and changes of EDSS and brain volume at Month 15, allowed the prediction of long-term EDSS change with a precision within one point in 38 of 49 patients (77.6%).
The number of new T 2 lesions, which was the strongest MRI predictor at univariate analysis, was correlated to 15-month EDSS change (r = 0.27, P = 0.046). However, since the 15-month EDSS change was the better related of the two, new T 2 lesions were not retained in the multivariate model of predictors.
Discussion
In this long-term longitudinal study, we found that the integration of clinical and imaging measures obtained at baseline and after a relatively short follow-up (15 months) resulted in earlier prognostication of longterm clinical worsening in PPMS. Around 78% of patients with clinical deterioration at 15 years could be identified 4 years before it would have been possible with simple clinical evaluation alone.
The final integrated model included baseline EDSS, 15-month EDSS change, baseline grey matter mean diffusivity, 15-month new T 1 -hypointense lesions and percentage brain volume change as predictors of long-term clinical outcome.
The notion that lower baseline EDSS scores and their short-term changes are associated with a higher risk of subsequent clinical worsening agrees with several previous studies in PPMS, with shorter follow-up (up to 10 years) (Sastre-Garriga et al., 2005; Rovaris et al., 2006; Khaleeli et al., 2008) . This also fits with the view that EDSS responsiveness to actual clinical changes is higher for the lower scores of the scale. Clearly, such a different responsiveness may also be the result of a plateauing effect, favouring lower EDSS scores. Furthermore, the importance of grey Roxburgh et al. (2005) . matter damage (Correale et al., 2017) , quantified in our study using diffusion tensor MRI, in explaining long-term clinical outcome is consistent with previous studies, not only in PPMS patients (Rovaris et al., 2006) , but also in those with relapse-onset multiple sclerosis (Filippi et al., 2013) , thus strengthening the motivation to include measures of grey matter involvement when monitoring multiple sclerosis evolution.
A few relatively recent long-term studies in multiple sclerosis patients in general (not necessarily those with the primary progressive course of the disease) have consistently shown that imaging parameters measured in the early stages of patient monitoring, carry important pieces of long-term prognostic information. For example, the volume of brain T 2 lesions has shown a predictive role for long-term accumulation of disability (including mortality) in studies with a follow-up duration up to 21 years (Goodin et al., 2012) , while the importance of grey matter damage for long-term disability (and cognitive impairment) has been demonstrated by atrophy and magnetization transfer MRI investigations (Filippi et al., 2013) . Because of variations between different published studies (duration of disease, length of follow-up and differences between MRI variables analysed), it is difficult to generalize from these studies at this stage. However, the MRI measures used in the future to predict long-term outcomes will most likely be dependent on the multiple sclerosis phenotype.
Other MRI measures of long-term clinical outcome in our PPMS cohort included were the formation of new T 1 -hypointense lesions and the progression of brain atrophy at 15 months. Both of these reflect neurodegenerative processes, which may not be clinically relevant in the initial stages of the disease, but which confer a susceptibility to disease worsening later on. Notably, in line with the results of another 10-year study in PPMS patients (Khaleeli et al., 2008) , measures of cervical cord atrophy, which were predictive in a 5-year study (Sastre-Garriga et al., 2005) , did not show a statistical significance at long-term. This is not unexpected, because cervical cord involvement is likely to explain the early clinical manifestations of PPMS, probably reaching a ceiling over time.
Earlier identification of those patients who will have a worse clinical outcome over time is important in multiple sclerosis, given the wide spectrum of available treatments. While this has long been perceived as crucial for patients with relapse-onset forms of the disease in order to guide timely treatment choices , the recent demonstration of treatment efficacy in PPMS (Tourbah et al., 2016; Montalban et al., 2017) has changed the clinical scenario for those patients with this rare form of the disease. Knowing 4 years in advance which patients will have the more severe disease progression may aid treatment decision-making, helping to minimize costs.
Our study has a uniquely long follow-up period for this patient group, and included both conventional and advanced MRI measures of the brain and spinal cord, collected and analysed centrally. However, it is not free from limitations. Clinical evaluation was simply based on EDSS rating and did not include assessment of ambulation and cognition (Penny et al., 2010) , which contribute to PPMS clinical manifestations. Imaging was based on the best strategies available at the time of enrolment, and many improvements have occurred in the interim. This may also help to explain the misclassification of $20% of our patients at the 15-year follow-up.
As a consequence, to be useful in counselling individual PPMS patients, further studies are needed, which should not only enrol larger numbers of patients (including patients at the very beginning of the disease), but also widen the clinical outcome measures and include other MRI measures (e.g. grey matter lesions, cord and brain grey matter atrophy, etc.). The value of a similar integrated approach in patients with the relapsing course of the disease, in whom treatment decisions are more complex, also warrants investigation.
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